Coland, ScinoPharm To Partner For Cancer Drugs In Mainland China
This article was originally published in PharmAsia News
Hong Kong's Coland Holdings and ScinoPharm Taiwan plan to collaborate with a yet-to-be-chosen third company in developing generic cancer drugs on the China mainland.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.